Eastern Connecticut Hematology/Oncology Assoc.

Norwich, Connecticut 06360

0 studies enrolling now · 7 studies all time

What they study most

Breast Cancer, Colorectal Neoplasms, Metastatic Castration-sensitive Prostate Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Prostate Cancer, Non-small Cell Lung Cancer, Solid Tumors

Studies at this site

• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy — Recruiting now
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) — Running, not enrolling
• Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] — Running, not enrolling
• M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) — Completed
• MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors — Completed
• A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer — Completed
• Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) — Completed